Weiss Asset Management LP Makes New Investment in Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Weiss Asset Management LP acquired a new stake in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 510,407 shares of the company’s stock, valued at approximately $20,273,000. Weiss Asset Management LP owned 0.34% of Centessa Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Millennium Management LLC increased its position in shares of Centessa Pharmaceuticals by 52.9% during the 1st quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after purchasing an additional 210,737 shares in the last quarter. Jane Street Group LLC bought a new stake in Centessa Pharmaceuticals during the first quarter worth about $2,176,000. Geode Capital Management LLC grew its stake in Centessa Pharmaceuticals by 44.7% during the second quarter. Geode Capital Management LLC now owns 87,435 shares of the company’s stock worth $1,149,000 after buying an additional 26,994 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Centessa Pharmaceuticals by 155.4% during the second quarter. JPMorgan Chase & Co. now owns 428,434 shares of the company’s stock worth $5,630,000 after buying an additional 260,702 shares in the last quarter. Finally, Legal & General Group Plc increased its holdings in shares of Centessa Pharmaceuticals by 29.2% during the second quarter. Legal & General Group Plc now owns 98,256 shares of the company’s stock worth $1,291,000 after buying an additional 22,205 shares in the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Analyst Ratings Changes

CNTA has been the topic of several recent analyst reports. Lifesci Capital downgraded Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 1st. Truist Financial cut Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a report on Monday, April 13th. Guggenheim downgraded Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. B. Riley Financial lowered Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, March 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Four research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $41.33.

Centessa Pharmaceuticals Price Performance

NASDAQ:CNTA opened at $40.50 on Friday. The company has a market cap of $6.27 billion, a price-to-earnings ratio of -22.63 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53. The stock’s fifty day moving average price is $40.14 and its two-hundred day moving average price is $33.69. Centessa Pharmaceuticals PLC Sponsored ADR has a 52-week low of $12.74 and a 52-week high of $40.56.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Tuesday, May 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.14). On average, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.